Head: Sofia Benkhelifa-Ziyyat
MyoVector produces gene therapy vectors from adeno-associated viruses (AAV) with a high level of quality and complete traceability of the final product. AAV vectors are used to express therapeutic transgenes, reporter genes (GFP, luciferase, LacZ, mSEAP) or other constructs (CrispCas9, shRNA, U7snRNA).
By combining our expertise with the expertise of Genethon, a scalable production method for preclinical and clinical applications is currently being developed in MyoVector with the support of the DIM Thérapie Génique.
In 2022, MyoVector supplied vectors to 8 teams at the Research Centre and contributed to 5 publications.
